Clinical trials: Movement Abnormalities
Parkinson Disease
Vibrotactile Coordinated Reset: A Non-invasive Treatment for Parkinson's Disease 2
The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on motor function in people with Parkinson's disease (PD).
- Trial name
- NCT05881460
- Testing
- Active vibrotactile coordinated reset
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Synergic Medical Technologies, Inc.
Parkinson's Disease
18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
The purpose of this study is to determine the long-term efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor…
- Trial name
- NCT01286935
- Testing
- Safinamide
- Volunteers
- 544 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease
A Study to Examine APL-130277 in Patients With Parkinson's Disease
The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)
- Trial name
- NCT02228590
- Testing
- APL-130277
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sumitomo Pharma America, Inc.
Parkinson's Disease
Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which means it affects the brain. This study will evaluate how ABBV-951 is absorbed under the skin of participants with PD when administered to arm, thigh and flank compared…
- Trial name
- NCT05094050
- Testing
- ABBV-951
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- AbbVie
Essential Tremor
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
The primary purpose of this study is to evaluate the long-term safety and tolerability of SAGE-324 in participants with essential tremor (ET).
- Trial name
- NCT05366751
- Testing
- SAGE-324
- Where
- 38 sites in United States
- Volunteers
- 97 people
- Sponsor
- Sage Therapeutics
Parkinson Disease
A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.
- Trial name
- NCT04435431
- Testing
- Mesdopetam
- Where
- 44 sites in United States, France and 4 more
- Volunteers
- 155 people
- Sponsor
- Integrative Research Laboratories AB
Parkinson Disease, Tremor
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual…
- Trial name
- NCT05642442
- Testing
- Suvecaltamide
- Where
- 37 sites in United States, Germany and 2 more
- Volunteers
- 169 people
- Sponsor
- Jazz Pharmaceuticals
Multiple System Atrophy
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
The primary objectives are to evaluate the safety and tolerability of multiple doses of ION464 administered via intrathecal (IT) injection (Part 1) and to evaluate the long-term safety and tolerability of ION464 (Part 2) in…
- Trial name
- HORIZON (NCT04165486)
- Testing
- ION464
- Where
- 15 sites in Austria, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Parkinson Disease, Movement Disorders
Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions
This study is a follow up to the HP-CD-CL-2002 clinical study. It evaluates the long-term safety in patients with Parkinson's disease after implantation of an investigational drug delivery system (DDS) with or without infusions…
- Conditions
- Parkinson Disease, Movement Disorders, Neuro-Degenerative Disease, Nervous System Diseases
- Trial name
- NCT04228653
- Testing
- Renishaw Drug Delivery System
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 15 people
- Sponsor
- Renishaw
Alzheimer's Disease, Huntington's Disease
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.
- Trial name
- NCT00931073
- Testing
- Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Parkinson Disease
Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101
This is a Phase I, double-blind, randomised, two-part, single-ascending dose (Part 1) and multiple-ascending dose (Part 2) study of NM-101 in healthy males and healthy females of non-childbearing potential
- Trial name
- NCT05790382
- Testing
- NM-101
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Neuramedy Co. Ltd.
Huntington's Disease
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.
- Trial name
- MermaiHD (NCT00665223)
- Testing
- ACR16
- Where
- 31 sites in Austria, Belgium and 6 more
- Volunteers
- 437 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson's Disease
Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)
An extension study for subjects with prior participation in previous resonator studies using low level magnetic fields to treat some of the symptoms of idiopathic Parkinson's Disease.
- Trial name
- NCT00862537
- Testing
- Resonator Device
- Volunteers
- 18 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC
Parkinson's Disease, Tremor
A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease
This is a Phase 2, multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks, a 4 week randomized double-blind, dose-titration treatment period, followed by a 1 week…
- Trial name
- NCT03436953
- Testing
- CX-8998
- Sponsor
- Jazz Pharmaceuticals
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Parkinson Disease
A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
This study will be an open-label, randomized, three-period cross-over pharmacokinetic evaluation of CVT-301 compared with the Reference Listed Drug (RLD), orally administered carbidopa/levodopa, in healthy volunteers.
- Trial name
- NCT02812394
- Testing
- CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Acorda Therapeutics
Parkinson Disease
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
- Trial name
- NCT06978920
- Testing
- Allogeneic dopaminergic neural precursor cell(NCR201)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Parkinson's Disease
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).
- Trial name
- BeyoND (NCT02726386)
- Testing
- ND0612
- Where
- 57 sites in United States, Austria and 7 more
- Volunteers
- 214 people
- Sponsor
- NeuroDerm Ltd.
Parkinson's Disease
Long Term Follow-Up Study for rAAV-GAD Treated Subjects
The purpose of this observational study is the long term follow-up of Parkinson's patients who participated in a clinical trial in which they received AAV-GAD gene transfer into the subthalamic nucleus (STN) region of the brain.
- Trial name
- NCT01301573
- Testing
- rAAV-GAD
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Neurologix, Inc.
Parkinson Disease
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as…
- Trial name
- NCT02172573
- Testing
- Pramipexole, Bromocriptine
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.